A comprehensive view of Phase 2 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Johnson & Johnson acquires Yellow Jersey for $1.25B to strengthen atopic dermatitis pipeline; NM26 set to enter Phase 2 studies, targeting IL-4Rα and IL-31 pathways
Published: July 11, 2024 by Johnson & Johnson Services Inc.
Johnson & Johnson completes $1.25 billion acquisition of Yellow Jersey Therapeutics; gains NM26, a Phase 2-ready bispecific antibody for atopic dermatitis and other immune diseases
Published: July 11, 2024 by Janssen Pharmaceutical Companies
Roche halts SKYSCRAPER-06 trial for metastatic non-squamous non-small cell lung cancer; tiragolumab and Tecentriq combo showed reduced efficacy, missing primary endpoints
Published: July 04, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Biogen completes acquisition of Human Immunology Biosciences; Biogen aims to advance felzartamab to Phase 3 and strengthen its presence in immunology
Published: July 02, 2024 by Biogen Inc.
Roche's PiaSky poised to become first monthly subcutaneous treatment for PNH in the EU; CHMP positive opinion based on COMMODORE 2 study showing comparable safety to IV eculizumab
Published: June 28, 2024 by F. Hoffmann-La Roche Ltd. (Roche)

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count